RXI 109

Drug Profile

RXI 109

Alternative Names: RXI-109

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator RXi Pharmaceuticals
  • Class Oligonucleotides; Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Keloids; Scars
  • Phase I/II Retinal disorders

Most Recent Events

  • 13 Dec 2016 Adverse events data from a phase IIa trial in Scars released by RXi Pharmaceuticals
  • 12 Aug 2016 RXi Pharmaceuticals completes enrolment in its phase IIa (RXI-109-1402) trial for Scars in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Scars in Honduras (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top